88 related articles for article (PubMed ID: 10526627)
1. Comparison of different tracers in the follow up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Mikosch P; Kresnik E; Gomez I; Kumnig G; Matschnig S; Unterweger O; Dinges HP; Starlinger M
Acta Med Austriaca; 1999; 26(4):115-7. PubMed ID: 10526627
[TBL] [Abstract][Full Text] [Related]
2. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
3. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
5. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
6. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
8. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG-PET in the follow-up of thyroid cancer.
Lind P; Kresnik E; Kumnig G; Gallowitsch HJ; Igerc I; Matschnig S; Gomez I
Acta Med Austriaca; 2003; 30(1):17-21. PubMed ID: 12558561
[TBL] [Abstract][Full Text] [Related]
11. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
13. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
[TBL] [Abstract][Full Text] [Related]
14. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.
Rubello D; Salvatori M; Casara D; Piotto A; Toniato A; Gross MD; Al-Nahhas A; Muzzio PC; Pelizzo MR
Eur J Surg Oncol; 2007 Sep; 33(7):902-6. PubMed ID: 17267163
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma.
Lips P; Comans EF; Hoekstra OS; van der Poest Clement E; van Mourik JC; Teule GJ
Neth J Med; 2000 Oct; 57(4):150-6. PubMed ID: 11006491
[TBL] [Abstract][Full Text] [Related]
17. [Value of F-18 fluorodeoxyglucose positron emission tomography in thyroid carcinoma].
Kumnig G
Wien Med Wochenschr; 2002; 152(11-12):280-5. PubMed ID: 12138656
[TBL] [Abstract][Full Text] [Related]
18. Radio-guided surgery for non-131I-avid thyroid cancer.
Rubello D; Pelizzo MR; Casara D; Piotto A; Toniato A; Fig L; Gross M
Thyroid; 2006 Nov; 16(11):1105-11. PubMed ID: 17123337
[TBL] [Abstract][Full Text] [Related]
19. Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma--preliminary results.
Gallowitsch HJ; Kresnik E; Mikosch P; Pipam W; Gomez I; Lind P
Nuklearmedizin; 1996 Dec; 35(6):230-5. PubMed ID: 8976503
[TBL] [Abstract][Full Text] [Related]
20. 131I whole body scintigraphy in thyroid cancer patients.
Lind P
Q J Nucl Med; 1999 Sep; 43(3):188-94. PubMed ID: 10568134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
